Skip to content

The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00502437
Enrollment
Unknown
Registered
2007-07-17
Start date
Unknown
Completion date
Unknown
Last updated
2010-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiemetic, Antiggaging Effect, Dental Situations, Gag Reflex, Granisetron

Brief summary

Antigagging effect of kytril (granisetron) an antiemetic drug in dental situations Gagging in dental situations can be a problem to the patient and the operating dentist. There are not proven methods of eliminating this reflex which sometimes will not allow routine quality dental care. Pharmacological and behavioral approaches to eliminate this reflex have been tried with limited success. This suggested study will test a potent antiemetic drug used in other clinical situations such as antineoplastic treatment. Granisetron is a potential antagonist for the 5-hydroxytryptamine3-receptor - 5HT(3), The drug binds to the receptor and blocks the effect of nausea and vomiting. Kytril mechanism of action was successfully proven for various medical situations as a potential antiemetic agent. Our Center for dental sedation and anesthesia in the oral medicine department have received approval to use Granisetron as an antigagging drug in dental situations based on several pilot studies conducted in other medical centers in different clinical situations such as strabismus corrections, post hysterectomy and others. Our preliminary clinical impression is that pre-emptive IV administration of this drug to patients with increased gag reflex is beneficial. In our research we try to investigate the possibility of using kytril in dental situations. In the first stage of this research we will study the INTRAVENOUS use of this drug and its effects On normal subjects compare them to themselves with placebo. According to the results of this study we will go on to the second stage of the research and try the same drug under oral administration. The purpose of this study is to test the antigagging effect of this drug in a controlled manner in dental situations. Our working hypothesis is that administration of this drug in dental situations with success, will allow many patients to receive good dental care

Interventions

DRUGGRANISETRON

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Intervention model
CROSSOVER
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* normal subjects

Exclusion criteria

* presence of systemic disease * subjects under medication or drug or food complementary agents

Countries

Israel

Contacts

Primary ContactEliezer Kaufman, Professor
ekaufman@cc.huji.ac.il+972.2.6776121
Backup ContactSilvina Friedlander-Barenboim, DMD
silvina@hadassah.org.il+972.2.6776157

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026